## All For Kids Pediatric Clinic Asthma Action Plan

| 71111 01 11103   | Cala   | ciic cii  | 1116 / (5011111   | a / (Ctioii   | ı ıdıı  |  |  |
|--|--|---|---|---|---|--|--|
| Name   | Date of Birth  | 1   | Date / /  |   | GREEN means Go!   |  |  |
| Health Care Provider   | Provider's Ph  | none  |   |   | Jse CONTROL medicine daily YELLOW means Caution!          |  |  |
| Parent/Responsible Person  | Parent's Pho   | arent's Phone School TELLOW Add RESCU   |   |   |   |  |  |
| Additional Emergency Contact   | Contact Pho  | ine   |   |   | RED means EMERGENCY!  Get help from a doctor no <u>w!</u> |  |  |
| Asthma Severity  ☐ Intermittent or ☐ Persistent: ☐ Mild ☐ Moderate ☐ Severe  Asthma Control ☐ Well-controlled ☐ Needs better cont  | ☐ Colds☐ Stron☐ Stress                                       | g odors $\square$ Ms/emotions $\square$   | _   | ☐ Exercise  | s Last Flu<br>Shot:                                       |  |  |
| Green Zone: Go! Take   | these CC   | NTROL (P  | REVENTION) Med  | dicines EVERY [   | Day   |  |  |
| You have ALL of these:  Breathing is easy  No cough or wheeze  Can work and play  Can sleep all night  Peak flow in this area:  to  (More than 80% of Personal Best)  Personal best peak flow: | Inhaled corticos Inhaled corticos Leukotriene ant For asthma | agonist   | osteroid/long-acting β-agonist β-agonist , , , , , , , , , , , , , , , , , , ,  | nebulizer treatmer  | spacer times a day  nt(s) times a day  e daily at bedtime |  |  |
| Yellow Zone: Caution!-   | Continu  | e CONTRO  | L Medicines and A   | ADD RESCU   | JE Medicines  |  |  |
| You have ANY of these:  • First sign of a cold  • Cough or mild wheeze  • Tight chest  • Problems sleeping, working, or playing  | OR   | lled β–agonist  | puff(s) MDI with sp   |   |   |  |  |
| Peak flow in this area:to  | Cally  |   | f you have these signs n  |   |   |  |  |
| (50%-80% of Personal Best)   |  | a week, o   | r if your rescue medicing   | e doesn't work!   |   |  |  |
| Red Zone: EMERGENCY!-  | - Conti  | inue CONT   | ROL & RESCUE N  | Medicines and G   | ET HELP!  |  |  |
| You have ANY of these:  Can't talk, eat, or walk well  Medicine is not helping Breathing hard and fast Blue lips and fingernails Tired or lethargic  | Fast-acting inha  OR Fast-acting inha                        | led β–agonist   | puff(s) MDI with space nebulizer treatment  | every 15 minutes,   | for <u>THREE</u> treatments                               |  |  |
| • Ribs show  | Other  |   |   |   |   |  |  |
| Peak flow in this area:  Less than   | IF YOU C   |   | TACT YOUR DOCTO   |   | mbulance  |  |  |
| (Less than 50% of Personal Best)   |  | or go a   | irectly to the Emerge   | ency Department!  |   |  |  |
| REQUIRED Healthcare Provider Signatur  Date: _ REQUIRED Responsible Person Signatur Date: _  |  | Possible side effect Healthcare ProvideThis studentThis student As the RESPONSIBI I hereby aut student. | is capable and approved to self-<br>is n <u>ot</u> approved to self-medic<br>.E PERSON:<br>horize a trained school employed | terol) include tachycardia, trend-<br>-administer the medicine(s) na<br>tate.<br>e, if available, to administer m | nor, and nervousness.  amed above.  dedication to the     |  |  |
|  |  | ☐ I hereby aut  | horize the student to possess an  | d self-administer medication.   |   |  |  |



Adapted from NAEPP by Children's National Medical Center Coordinated by the National Capital Asthma Coalition

## Stepwise Approach for Managing Asthma in Children and Adults (from 2007 NAEPP Guidelines)

|   |                                   |                | IMPAIR                                       | MENT              | RISK  |  |   |  |  |
|---|-----------------------------------|----------------|--|-------------------|---|--|---|--|--|
| Criteria apply<br>to all ages<br>unless<br>otherwise<br>indicated | rise                              |                | Nighttime<br>Awakenings<br>(5 years ≥5 years |                   | Short-<br>acting<br>beta-<br>agonist<br>use | FEV <sub>1</sub> % predicted (n/a in age <5) | Exacerbations<br>requiring<br>oral systemic<br>corticosteroids              |  |  |
| Classification of<br>Consider severity                            |                                   | Step           |  |                   |   |  |   |  |  |
| Severe<br>Persistent  | Throughout<br>the day             | >1x/week       | Often<br>7x/week                             | Extremely limited | Several x/<br>day                           | <60%   | <5: ≥2 in 6<br>months OR<br>≥4 wheezing<br>episodes in 1<br>year lasting >1 | <5: Step 3 5-11: Step 3 Medium-dose ICS option or Step 4 12-adult: Step 4 or 5 All ages: Consider short course OCS |  |
| Moderate<br>Persistent  | Daily                             | 3-4x/<br>month | >1x/week<br>but not<br>nightly               | Some              | Daily                                       | 60-80%                                       | day AND risk<br>factors for per-<br>sistent asthma                          | <5: Step 3 5-11: Step 3 Medium-dose ICS option 12-adult: Step 3 All ages: Consider short course OCS                |  |
| Mild<br>Persistent  | >2 days/<br>week but<br>not daily | 1-2x/<br>month | 3-4x/<br>month                               | Minor             | >2 days/<br>week but<br>not daily           | >80%   | <b>5-adult:</b><br>≥2/year  | Step 2   |  |
| Intermittent  | ≤2 days/week                      | 0              | ≤2x/<br>month                                | None              | ≤2 days/<br>week                            | >80%   | 0-1/year  | Step 1   |  |

| Classification of<br>Consider severity a | <b>Action:</b> In children <5, consider alternate diagnosis or adjusting therapy if no benefit seen in 4-6 weeks. |               |               |                   |                      |        |                                |  |
|--|---|---------------|---------------|-------------------|----------------------|--------|--------------------------------|--|
| Very Poorly<br>Controlled                | Throughout<br>the day   | ≥2x/week      | ≥4x/week      | Extremely limited | Several<br>times/day | <60%   | <5: >3/year  5-adult: ≥2/year  | Step up 1-2 steps. Consider short course OCS. Reevaluate in 2 weeks. For side effects, consider alternate treatment. |
| Not Well<br>Controlled                   | >2 days/<br>week  | ≥2x/<br>month | 1-3x/week     | Some              | >2 days/<br>week     | 60-80% | <5: 2-3/year  5-adult: ≥2/year | Step up at least 1 step.<br>Reevaluate in 2-6 weeks.<br>For side effects, consider alternate<br>treatment.           |
| Well<br>Controlled                       | ≤2 days/<br>week  | ≤1x/<br>month | ≤2x/<br>month | None              | ≤2 days/<br>week     | >80%   | 0-1/year                       | Maintain current treatment. Follow-up every 1-6 months. Consider step down if well controlled for at least 3 months. |

| <b>Daily Doses</b> of common inhaled corticosteroids | Low    | Fluticason<br>MDI (mcg)<br>Medium | <b>e</b><br>High |          | <b>Budesonic</b><br>Respules (m<br>Medium | -   | <b>Be</b> | clomethas<br>MDI (mcg)<br>Medium | <b>one</b><br>High | Fluticasone/<br>Salmeterol<br>DPI | Budesonide/<br>Formoterol<br>MDI |
|--|--------|-----------------------------------|------------------|----------|---|-----|-----------|----------------------------------|--------------------|-----------------------------------|----------------------------------|
| <5 years   | 176    | >176-352                          | >352             | 0.25-0.5 | >0.5-1                                    | >1  |           | n/a                              |                    | n/a                               | n/a                              |
| 5-11 years   | 88-176 | >176-352                          | >352             | 0.5      | 1   | 2   | 80-160    | >160-320                         | >320               | 100/50 mcg<br>1 inhalation BID    | 80 mcg/4.5 mcg<br>2 puffs BID    |
| 12 years-adult                                       | 88-264 | >264-440                          | >440             | n/a      | n/a                                       | n/a | 80-240    | >240-480                         | >480               | Dose depends on patient           | Dose depends on patient          |

SABA: Short-acting beta-agonist LABA: Long-acting beta-agonist LTRA: Leukotriene-receptor antagonist

ICS: Inhaled corticosteroids LD-ICS: Low-dose ICS MD-ICS: Medium-dose ICS HD-ICS: High-dose ICS OCS: Oral corticosteroids

CRM: Cromolyn NCM: Nedocromil THE: Theophylline MLK: Montelukast ALT: Alternative

Step 1

**Preferred** SABA prn

Step 2

**Preferred** LD-ICS

<u>Alternative</u> <5: CRM or MLK

5-adult: CRM, LTRA, NCM, THE Step 3

**Preferred** <5: MD-ICS

5-11: EITHER LD-ICS plus LABA, LTRA or THE OR MD-ICS

12-adult: LD-ICS plus LABA **OR** MD-ICS

<u>Alternative</u>

12-adult: LD-ICS plus either LTRA, THE or zileuton

Step 4

**Preferred** 

<5: Medium-dose ICS plus either LABA or MLK

5-adult: MD-ICS plus LABA

<u>Alternative</u> 5-11: MD-ICS plus either LTRA or THE

**12-adult:** MD-ICS *plus* either LTRA, THE or zileuton

Step 5

**Preferred** 

<5: HD-ICS plus either LABA or MLK

5-11: HD-ICS plus LABA

High-dose ICS plus LABA AND consider Omalizumab for patients who have allergies

<u>Alternative</u>

5-11: HD-ICS plus either LTRA or THE

Step 6

**Preferred** 

<5: HD-ICS plus either LABA or MLK plus OCS

**5-11:** HD-ICS plus LABA plus OCS

12-adult:

HD-ICS plus LABA plus OCS AND consider Omalizumab for patients who have allergies

<u>Alternative</u>

5-11: HD-ICS plus either LTRA or THE plus OCS

-Step down if possible (asthma well-controlled at least 3 months)/Step up if needed (check adherence, technique, environment, co-morbidities)